SCHEMBL19586331

SCHEMBL19586331

COC(=O)c1ccc(=O)n(C2CCC(=O)NC2=O)c1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CRBN Q96SW2 15/20 0.44
DDB1 Q16531 11/20 0.44
IKZF3 Q9UKT9 4/20 0.41
ALDH1A1 P00352 1/20 0.41
CHRM2 P08172 1/20 0.41
OPRM1 P35372 1/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.41
MAP1LC3B Q9GZQ8 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19585379 0.87 CRBN (0.42) ALOX15HSD17B10CRBNDDB1IKZF3
SCHEMBL19585639 0.85 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL23589797 0.82 CRBN (0.41) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL6206941 0.77 ALDH1A1 (0.48) HSD17B10ALDH1A1TSHRTDP1LMNA
SCHEMBL924151 0.74 ALDH1A1 (0.52) HSD17B10ALDH1A1CYP1A2TSHRTDP1
SCHEMBL24132070 0.74 CRBN (0.49) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL924256 0.73 ALDH1A1 (0.54) ALOX15HSD17B10ALDH1A1CYP1A2TSHR
Trifluoroacetic Acid SCHEMBL19585232 0.72 CRBN (0.44) CRBNDDB1IKZF3CYP1A2TSHR
SCHEMBL31313969 0.71 LMNA (0.41) HSD17B10ALDH1A1TSHRTDP1LMNA
SCHEMBL24414115 0.71 CRBN (0.42) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-04-24 US disclosed
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation C4 THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-10-06 US disclosed
EP-3455219-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2019-03-20 EP disclosed
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
WO-2017197051-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed
WO-2017197051-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 ALOX15 3907/4885HSD17B10 1768/4885CRBN 77/4885
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION GCGR, STUB1, GID4 ALOX15 2852/4885HSD17B10 714/4885CRBN 23/4885
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 ALOX15 3907/4885HSD17B10 1768/4885CRBN 77/4885
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation GID4, RNF5, UBE3C ALOX15 3327/4885HSD17B10 1129/4885CRBN 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.